APC News Feed | Stay Updated on Pharmacy Compounding

Kentucky, Alabama weigh in on peptides and GLP-1s

Written by Sean Waldron | Nov 20, 2026

Three recent state board communications underscore the increasingly complicated regulatory landscape for pharmacy compounding.

Kentucky has expressly rejected HHS's interim enforcement discretion policy for six peptides. In a November 19 compliance alert, the Kentucky Board of Pharmacy announced that neither resident nor nonresident pharmacies may compound or dispense preparations containing BPC-157, TB-500, epitalon, semax, KPV, or MOTS-c for Kentucky patients. The board cites existing state regulation and says it will grant no waivers.

Meanwhile, the Alabama Board of Medical Examiners has published a November 10 FAQ emphasizing that HHS enforcement discretion neither overrides state law nor establishes compliance with Section 503A. Unlike Kentucky, Alabama has not announced a new prohibition, but its guidance raises questions about whether pharmacies can rely on the federal policy.

Separately, the Alabama Board of Pharmacy issued a GLP-1 compounding advisory emphasizing individualized prescriber determinations of significant difference and cautioning against routine ingredient additions, standardized justifications, and preselected prescribing-platform responses.

The takeaway: Federal policy does not guarantee uniform state treatment. APC continues urging federal-state coordination and greater regulatory clarity while reminding pharmacies to verify applicable state requirements.